Tigecycline

C. diff Risk

Medium

Oral Bioavailability

NA

Approximate Cost

Spectrum Of Activity

Dosing

100 mg IV once, then 50 mg IV q12h

No dose adjustment

General Information

Common Usage

Reserved for highly resistant infections or when significant allergies restrict other options and when there is documented susceptibility

Associated with more treatment failures than alternatives and excess mortality - Black Box Warning

Adverse Effects

Avoid or use with caution in patients with tetracycline reactions

GI side effects very prominent with significant nausea and vomiting

Tetracycline related adverse events: photosensitivity, acute pancreatitis

Rash, abnormal liver enzymes

Major Interactions

Oral contraceptives less effective

Additional Information

Requires Infectious Disease consultation

Documented safety concerns in bacteremia

An increase in all-cause mortality has been observed in a meta-analysis of phase 3 and 4 clinical trials in tigecycline-treated patients versus comparator.

Pharmacology

Antimicrobial class: Tetracycline derivative

Pregnancy category: D

Average serum half life: 42.0

Lung penetration: Therapeutic

Biliary penetration: Therapeutic